{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:33:51Z","timestamp":1792802031808,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jcf.2023.03.002","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T17:40:42Z","timestamp":1679506842000},"page":"730-737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":145,"title":["Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study"],"prefix":"10.1016","volume":"22","author":[{"given":"Julie K.","family":"Bower","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Volkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Ahluwalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurvaneet","family":"Sahota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjuan","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya G.","family":"Weinstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Ostrenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Elbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4922","key":"10.1016\/j.jcf.2023.03.002_bib0001","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"issue":"9678","key":"10.1016\/j.jcf.2023.03.002_bib0002","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jcf.2023.03.002_bib0003","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"10059","key":"10.1016\/j.jcf.2023.03.002_bib0004","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2023.03.002_bib0005","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1146\/annurev.biochem.75.103004.142532","article-title":"CFTR function and prospects for therapy","volume":"77","author":"Riordan","year":"2008","journal-title":"Annu Rev Biochem"},{"issue":"44","key":"10.1016\/j.jcf.2023.03.002_bib0006","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"10.1016\/j.jcf.2023.03.002_bib0007","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445\u2013tezacaftor\u2013ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jcf.2023.03.002_bib0008","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jcf.2023.03.002_bib0009","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jcf.2023.03.002_bib0010","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jcf.2023.03.002_bib0011","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jcf.2020.04.015","article-title":"Tezacaftor\/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations","volume":"19","author":"Munck","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2023.03.002_bib0012","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: interim results of an open-label phase 3 clinical trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl\u00a02","key":"10.1016\/j.jcf.2023.03.002_bib0013","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/S1569-1993(22)00861-X","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from an open-label extension study","volume":"21","author":"Griese","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2023.03.002_bib0014","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","article-title":"The Cystic Fibrosis Foundation Patient Registry. Design and methods of a national observational disease registry","volume":"13","author":"Knapp","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2023.03.002_bib0015","series-title":"2021 Patient Registry: Annual Data Report","year":"2022"},{"issue":"1","key":"10.1016\/j.jcf.2023.03.002_bib0016","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.chest.2020.09.084","article-title":"Pulmonary exacerbations in adults with cystic fibrosis. A grown-up issue in a changing cystic fibrosis landscape","volume":"159","author":"Stanford","year":"2021","journal-title":"Chest"},{"issue":"23","key":"10.1016\/j.jcf.2023.03.002_bib0017","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMc2115966","article-title":"VX18-445-104 Study Group. Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes. Reply","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jcf.2023.03.002_bib0018","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thoraxjnl-2017-210394","article-title":"Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor","volume":"73","author":"Bessonova","year":"2018","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.jcf.2023.03.002_bib0019","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jcf.2019.07.008","article-title":"The impact of CFTR modulator therapies on CF airway microbiology","volume":"19","author":"Rogers","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.jcf.2023.03.002_bib0020","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/thoraxjnl-2014-205983","article-title":"Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries","volume":"69","author":"Quittner","year":"2014","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.jcf.2023.03.002_bib0021","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/ppul.25250","article-title":"Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID-19 pandemic","volume":"56","author":"Patel","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.jcf.2023.03.002_bib0022","first-page":"281","article-title":"CFTR modulators: transformative therapies for cystic fibrosis","volume":"27","author":"Dwight","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2023.03.002_sbref0023","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1569-1993(21)01602-7","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor therapy use on pulmonary exacerbation rates during the COVID-19 pandemic","volume":"20","author":"Menten","year":"2021","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T22:32:55Z","timestamp":1751581975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323000668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1569199323000668"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.03.002","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}